Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Supernus Pharm (SUPN)

Supernus Pharm (SUPN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,479,350
  • Shares Outstanding, K 54,974
  • Annual Sales, $ 607,520 K
  • Annual Income, $ 1,320 K
  • 60-Month Beta 0.93
  • Price/Sales 2.45
  • Price/Cash Flow 16.91
  • Price/Book 1.59
Trade SUPN with:

Options Overview Details

View History
  • Implied Volatility 36.88% ( -6.89%)
  • Historical Volatility 25.97%
  • IV Percentile 23%
  • IV Rank 46.06%
  • IV High 68.56% on 04/25/24
  • IV Low 9.83% on 08/18/23
  • Put/Call Vol Ratio 0.50
  • Today's Volume 6
  • Volume Avg (30-Day) 13
  • Put/Call OI Ratio 0.17
  • Today's Open Interest 846
  • Open Int (30-Day) 2,128

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate 0.25
  • Number of Estimates 2
  • High Estimate 0.30
  • Low Estimate 0.21
  • Prior Year -0.02
  • Growth Rate Est. (year over year) +1,350.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
25.53 +3.84%
on 06/14/24
28.34 -6.46%
on 06/04/24
-1.00 (-3.64%)
since 05/24/24
3-Month
25.53 +3.84%
on 06/14/24
34.49 -23.14%
on 04/04/24
-6.24 (-19.05%)
since 03/25/24
52-Week
21.99 +20.55%
on 10/27/23
35.44 -25.20%
on 03/21/24
-6.12 (-18.76%)
since 06/23/23

Most Recent Stories

More News
Supernus: Q4 Earnings Snapshot

Supernus: Q4 Earnings Snapshot

SUPN : 26.51 (-1.49%)
Supernus: Q3 Earnings Snapshot

Supernus: Q3 Earnings Snapshot

SUPN : 26.51 (-1.49%)
Supernus: Q2 Earnings Snapshot

Supernus: Q2 Earnings Snapshot

SUPN : 26.51 (-1.49%)
Despite 1 Major Headwind and Pricey Shares, This Stock Is Still a Buy

Supernus Pharmaceuticals' revenue mix is shifting, and it could soon have more sales on the way.

SUPN : 26.51 (-1.49%)
Supernus: Q1 Earnings Snapshot

Supernus: Q1 Earnings Snapshot

SUPN : 26.51 (-1.49%)
Supernus: Q4 Earnings Snapshot

Supernus: Q4 Earnings Snapshot

SUPN : 26.51 (-1.49%)
Supernus: Q3 Earnings Snapshot

Supernus: Q3 Earnings Snapshot

SUPN : 26.51 (-1.49%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Supernus Pharmaceuticals, Inc. - SUPN

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Supernus Pharmaceuticals, Inc. (""Supernus" or the "Company") (NASDAQ: SUPN)....

SUPN : 26.51 (-1.49%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Supernus Pharmaceuticals, Inc. - SUPN

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Supernus Pharmaceuticals, Inc. (""Supernus" or the "Company") (NASDAQ: SUPN)....

SUPN : 26.51 (-1.49%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Supernus Pharmaceuticals, Inc. - SUPN

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Supernus Pharmaceuticals, Inc. ("Supernus" or the "Company") (NASDAQ: SUPN)....

SUPN : 26.51 (-1.49%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strongest short term outlook on maintaining the current direction.

See More Share

Business Summary

Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. It is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit...

See More

Key Turning Points

3rd Resistance Point 27.50
2nd Resistance Point 27.27
1st Resistance Point 26.89
Last Price 26.51
1st Support Level 26.28
2nd Support Level 26.05
3rd Support Level 25.67

See More

52-Week High 35.44
Fibonacci 61.8% 30.30
Fibonacci 50% 28.72
Fibonacci 38.2% 27.13
Last Price 26.51
52-Week Low 21.99

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar